BioSpace News Archive

Rocket Pharmaceuticals to Present at Chardan 6th Annual Genetic Medicines Conference.

CytoSorbents Corporation announced that it has received ISO 13485 Certification of its new manufacturing facility in Princeton, New Jersey from its European Union notified body, clearing the way for full manufacturing of CytoSorb®, DrugSorb®-ATR, and ECOS-300CY® from this site, with capacity to add additional product lines as they are developed.

Imunon, Inc. today announced that Dr. Corinne Le Goff, President and Chief Executive Officer will present a company overview and be available for 1x1 meetings at the upcoming Chardan 6th Annual Genetic Medicines Conference.

Bellerophon Therapeutics, Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted the Company’s proposal to reduce the study size for its ongoing registrational REBUILD Phase 3 trial of INOpulse® for the treatment of fibrotic Interstitial Lung Disease (fILD).

Neurophth Therapeutics, Inc. (“Neurophth”) announced today that the first patient has been dosed in Phase III clinical trial for the treatment of Leber hereditary optic neuropathy (LHON).

B. Braun Medical Inc., a leader in infusion therapy and pain management, announced it has acquired the innovative Clik-FIX catheter securement device portfolio from Starboard Medical, Inc.

Evon Medics, LLC today announced that it has been awarded a non-dilutive grant of $2.9 million for its FAST-TRACK SBIR (Small Business Innovation Research) study for the development and evaluation of its Computerized Chemosensory-Based Orbitofrontal Networks Training for Treatment of Pain (CBOT-P).

Moleculin Biotech, Inc. announced its WP1096 molecule will be evaluated in animal studies through the preclinical services offered by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

RAIsonance, Inc., today announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of its AudibleHealth Dx Software as a Medical Device (SaMD).

Neogen Corporation (NASDAQ: NEOG) announced today the results of the first quarter of its 2023 fiscal year, which ended August 31.